AFT Pharmaceuticals Limited

ASX:AFP Stock Report

Market Cap: AU$254.9m

AFT Pharmaceuticals Valuation

Is AFP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AFP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AFP (A$2.22) is trading below our estimate of fair value (A$12.97)

Significantly Below Fair Value: AFP is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AFP?

Key metric: As AFP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AFP. This is calculated by dividing AFP's market cap by their current earnings.
What is AFP's PE Ratio?
PE Ratio24.5x
EarningsNZ$11.61m
Market CapNZ$284.19m

Price to Earnings Ratio vs Peers

How does AFP's PE Ratio compare to its peers?

The above table shows the PE ratio for AFP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average13.7x
VLS Vita Life Sciences
12.6xn/aAU$117.1m
VIT Vitura Health
16.2xn/aAU$57.0m
ECS ECS Botanics Holdings
12.1xn/aAU$21.9m
NEU Neuren Pharmaceuticals
13.8x-9.9%AU$1.6b
AFP AFT Pharmaceuticals
24.5x23.6%AU$284.2m

Price-To-Earnings vs Peers: AFP is expensive based on its Price-To-Earnings Ratio (24.5x) compared to the peer average (13.4x).

Price to Earnings Ratio vs Industry

How does AFP's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

23 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AFP 24.5xIndustry Avg. 22.5xNo. of Companies72PE01632486480+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AFP is expensive based on its Price-To-Earnings Ratio (24.5x) compared to the Global Pharmaceuticals industry average (22.5x).

Price to Earnings Ratio vs Fair Ratio

What is AFP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AFP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.5x
Fair PE Ratio19x

Price-To-Earnings vs Fair Ratio: AFP is expensive based on its Price-To-Earnings Ratio (24.5x) compared to the estimated Fair Price-To-Earnings Ratio (19x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AFP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$2.22
AU$3.42
+54.1%
21.1%AU$4.14AU$2.70n/a2
Nov ’25AU$2.79
AU$3.30
+18.1%
26.9%AU$4.18AU$2.41n/a2
Oct ’25AU$3.02
AU$3.44
+13.9%
22.7%AU$4.22AU$2.66n/a2
Sep ’25AU$2.87
AU$3.46
+20.7%
22.7%AU$4.25AU$2.68n/a2
Aug ’25AU$2.80
AU$3.46
+23.7%
22.7%AU$4.25AU$2.68n/a2
Jul ’25AU$2.85
AU$3.46
+21.5%
22.7%AU$4.25AU$2.68n/a2
Jun ’25AU$2.80
AU$3.46
+23.7%
22.7%AU$4.25AU$2.68n/a2
May ’25AU$2.79
AU$3.39
+21.6%
24.3%AU$4.22AU$2.57n/a2
Apr ’25AU$2.76
AU$3.39
+22.9%
24.3%AU$4.22AU$2.57n/a2
Mar ’25AU$3.10
AU$4.26
+37.4%
30.2%AU$5.79AU$2.64n/a3
Feb ’25AU$3.30
AU$4.38
+32.8%
22.6%AU$5.69AU$3.29n/a3
Jan ’25AU$3.25
AU$4.38
+34.8%
22.6%AU$5.69AU$3.29n/a3
Dec ’24AU$3.05
AU$4.20
+37.7%
21.5%AU$5.67AU$3.28n/a4
Nov ’24AU$3.20
AU$4.33
+35.5%
19.9%AU$5.77AU$3.57AU$2.794
Oct ’24n/a
AU$4.29
0%
19.7%AU$5.65AU$3.50AU$3.024
Sep ’24n/a
AU$4.29
0%
19.7%AU$5.65AU$3.50AU$2.874
Aug ’24AU$3.38
AU$3.94
+16.5%
9.3%AU$4.44AU$3.59AU$2.803
Jul ’24AU$3.40
AU$3.94
+15.8%
9.3%AU$4.44AU$3.59AU$2.853
Jun ’24AU$3.68
AU$3.94
+7.0%
9.3%AU$4.44AU$3.59AU$2.803
May ’24AU$3.20
AU$3.55
+10.8%
16.3%AU$4.29AU$2.88AU$2.793
Apr ’24AU$3.20
AU$3.55
+10.8%
16.3%AU$4.29AU$2.88AU$2.763
Mar ’24AU$3.25
AU$3.55
+9.1%
16.3%AU$4.29AU$2.88AU$3.103
Feb ’24AU$3.35
AU$3.55
+5.8%
16.3%AU$4.29AU$2.88AU$3.303
Jan ’24AU$3.40
AU$4.86
+42.9%
35.7%AU$7.67AU$2.94AU$3.254
Dec ’23AU$3.51
AU$4.86
+38.4%
35.7%AU$7.67AU$2.94AU$3.054
Nov ’23AU$3.24
AU$4.93
+52.1%
29.5%AU$7.38AU$3.57AU$3.204

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.14

7D

8.0%

1Y

10.2%

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.41

7D

-3.5%

1Y

-47.1%

AVITA Medical

US$349.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$4.20

7D

12.6%

1Y

27.7%